- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Telomir Pharmaceuticals, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 17.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models | 288 | ACCESS Newswire | Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)... ► Artikel lesen | |
| 17.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging | 719 | ACCESS Newswire | Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic... ► Artikel lesen | |
| 05.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.01. | Rodman & Renshaw initiates Telomir Pharma stock with Buy rating | 1 | Investing.com | ||
| 05.01. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models | 321 | ACCESS Newswire | In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire... ► Artikel lesen | |
| 05.01. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Telomir Pharmaceuticals beschließt neues Vergütungspaket für CEO | 3 | Investing.com Deutsch | ||
| 18.12.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development | 353 | ACCESS Newswire | No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir... ► Artikel lesen | |
| 17.12.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.11.25 | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 2 | Cision News | ||
| 25.11.25 | Telomir reports PSA reduction in prostate cancer cells with lead drug | 2 | Investing.com | ||
| 25.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells | 319 | ACCESS Newswire | PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November... ► Artikel lesen | |
| 21.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells | 401 | ACCESS Newswire | Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL... ► Artikel lesen | |
| 20.11.25 | Craig Eagle verlässt Aufsichtsrat von Telomir Pharmaceuticals | 1 | Investing.com Deutsch | ||
| 20.11.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine in Reducing Intracellular Iron in a Human Cell Line | 391 | ACCESS Newswire | New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating... ► Artikel lesen | |
| 12.11.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.25 | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,05 | -0,65 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| MODERNA | 45,490 | -1,77 % | Moderna Stock is Soaring. Is It Too Late to Buy? | ||
| VALNEVA | 2,838 | +0,28 % | K+S Aktie: Kaufpanik - Deutsche Telekom, Hamborner, Nel ASA, TUI und Valneva - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,310 | -2,24 % | Inovio Q4 2025 slides: BLA accepted but FDA questions linger | ||
| OCUGEN | 1,700 | -0,82 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,600 | -0,40 % | Why Viking Therapeutics Stock Could Take Off Later This Year | ||
| BAVARIAN NORDIC | 25,400 | -0,20 % | Bavarian Nordic A/S - Notice Convening Annual General Meeting | ||
| GERON | 1,321 | -1,46 % | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Achieved $48 million and $184 million in RYTELO (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within... ► Artikel lesen | |
| IMMUNITYBIO | 6,792 | -2,78 % | ImmunityBio-Aktie -21%: Buy the dip? | Es ist eine nervenaufreibende Woche für ImmunityBio-Aktionäre. Nachdem der Kurs des Biotech-Unternehmens am Montag +10% in die Höhe schoss, ging es am gestrigen Dienstag um atemberaubende -21% nach... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,253 | +0,42 % | Iovance Biotherapeutics: Aufsichtsratsmitglied Wendy Yarno kündigt Rücktritt an | ||
| ZAI LAB LTD ADR | 15,900 | -1,24 % | ZAI LAB (09688): NOTICE OF BOARD ACTION | ||
| VERASTEM | 4,140 | -2,82 % | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 15,252 | -0,26 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Full-year 2025 net product revenues of $689 million SYFOVRE- (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI- (pegcetacoplan) full year 2025 net product revenue... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,605 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| ANNOVIS BIO | 1,950 | +1,04 % | Annovis Bio: Finanzvorstand geht, CEO übernimmt kommissarisch |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,280 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.